| 33419-42-0 Basic information More.. |
Product Name: | Etoposide | Synonyms: | (-)-Etoposide, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside;EtoposideETOPOSIDE CAS:33419-42-0 MES-012;BMY-40481, Etoposide 4'-Dihydrogenphosphate, VP-16-213;Etoposide , 98.0%(LC);Etoposide for system suitability;GAL4 [(1-147) + VP16 (411-490)] from Saccharomyces cerevisiae human herpesvirus 2;Etoposide, >=98%;(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one | CAS: | 33419-42-0 | MF: | C29H32O13 | MW: | 588.56 | EINECS: | 251-509-1 | Mol File: | 33419-42-0.mol |  |
Use
Etoposide is used as anti-cancer drug mainly used for the treatment of small cell lung cancer, testicular cancer, malignant lymphoma and acute leukemia. It also has certain efficacy in treating neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, stomach cancer and breast cancer.
- Etoposide
-
- 2025-05-21
- CAS:33419-42-0
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Etoposide
-
- US $108.00-48.00 / mg
- 2025-05-21
- CAS:33419-42-0
- Min. Order:
- Purity: 99.95%
- Supply Ability: 10g
- Etoposide
-
- US $108.00-48.00 / mg
- 2025-05-21
- CAS:33419-42-0
- Min. Order:
- Purity: 99.95%
- Supply Ability: 10g
|
33419-42-0
Recommend Suppliers |
Company Name: |
Amadis Chemical Company Limited
Recommend
Complaint |
 |
Tel: |
571-89925085 |
FAX: |
0086-571-89925065 |
Email: |
sales@amadischem.com |
Nationality: |
China |
Products Intro: |
Product Name:(8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one CAS:33419-42-0 Purity:0.97 Package:mgs,gs,kgs Remarks:A821765 |
CB Index: |
58 |
WebSite: |
http://www.amadischem.com |
Related Information: |
Sales Network
Catalog(131957)
User Evaluation(2)
|
|
|
|
|
|